Catalyze: Product Definition Device Prototype Testing and Design Modification, Diagnostic Disease Target Assay Development and Design Characterization, and Research Tool Testing and Validation (R33 - Clinical Trials Not Allowed)
ID: 337524Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $250K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/337524

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-014.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Catalyze: Product Definition Device Prototype Testing and Design Modification," aimed at supporting early-stage translational research for prototype testing, assay development for diagnostic disease targets, and the creation of research tools related to heart, lung, blood, and sleep (HLBS) diseases. Eligible applicants include a diverse range of organizations such as higher education institutions, non-profits, and tribal colleges, with a total funding commitment projected at $6,277,500 annually over the fiscal years 2023-2025. This initiative emphasizes the importance of innovation in addressing significant gaps in existing technologies, requiring proposals to include a minimum of 25% non-federal cash match, an Accelerator Partner for commercialization support, and a detailed project management plan. Interested parties should note that applications are due by 5 PM local time on December 20, 2024, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    RFA-HL-23-014-Full-Announcement.html
    RFA-HL-23-014.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), announces a funding opportunity titled "Catalyze: Product Definition Device Prototype Testing and Design" under the R33 exploratory grants phase II. This funding aims to support early-stage translational research for prototype testing, assay development for diagnostic disease targets, and the creation of research tools pertaining to heart, lung, blood, and sleep (HLBS) diseases. Applications are sought from various eligible organizations, including higher education institutions and non-profits, with a total funding commitment projected at $6,277,500 annually over the fiscal years 2023-2025. Each application must include a minimum of 25% non-federal cash match of the direct federal costs, an Accelerator Partner for commercialization support, and a robust project management plan outlining specific milestones within a two-year project period. Proposals must demonstrate innovation by addressing significant gaps in existing technologies and providing detailed biological rationale backed by preliminary data. Key dates for submission include applications due by 5 PM local time on specified dates, with a project eligibility focused exclusively on device and diagnostic development, excluding clinical trials. The initiative underscores the commitment of the NIH to facilitate translation of innovative research into healthcare advancements.
    Similar Opportunities
    Catalyze: Product Definition Device Prototype Testing and Design Modification, Diagnostic Disease Target Assay Development and Design Characterization, and Research Tool Testing and Validation (R33 - Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Catalyze: Product Definition Device Prototype Testing and Design Modification, Diagnostic Disease Target Assay Development and Design Characterization, and Research Tool Testing and Validation" (RFA-HL-23-014). This grant aims to support early-stage translational research focused on developing devices, diagnostics, and research tools for heart, lung, blood, and sleep (HLBS) diseases, with an emphasis on prototype testing, user feedback, and regulatory strategies. The total funding available is up to $6.3 million per year, and applicants are required to provide substantial evidence of unmet medical needs and preliminary data, along with a minimum cash match of 25% from non-federal sources. Applications are due by December 20, 2024, and further inquiries can be directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov. More details can be found at the provided link: http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-014.html.
    Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research" grant, aimed at advancing technologies that address heart, lung, blood, and sleep (HLBS) disorders. This funding opportunity specifically seeks R33 exploratory/developmental grant applications that focus on mid-stage developments requiring further validation and refinement, with an emphasis on demonstrating novelty and substantial improvement over existing methods. The initiative is crucial for facilitating transformations in HLBS-related research and clinical practices, promoting the swift adoption of breakthrough technologies. Interested applicants can apply for funding of up to $1.86 million annually, with a submission deadline of December 20, 2024. For further inquiries, applicants may contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Catalyze: Product Definition for Small Molecules and Biologics - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Catalyze: Product Definition for Small Molecules and Biologics - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed)." This initiative aims to provide early-stage translational support for identifying and characterizing therapeutic candidates targeting heart, lung, blood, and sleep disorders, facilitating innovative projects that address critical therapeutic gaps. The program operates under a phased grant structure, with funding capped at $350,000 per year, and requires applicants to submit detailed project management plans and measurable milestones. Interested applicants must submit their proposals electronically through Grants.gov by December 20, 2024, and can direct inquiries to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed)" aimed at supporting early-stage translational research for developing therapeutic agents targeting heart, lung, blood, and sleep disorders. This initiative seeks to identify lead compound series and bridge the gap between basic science discoveries and preclinical testing, emphasizing innovation through novel therapeutic approaches and strong biological rationale. The grant offers a maximum funding amount of $350,000 over a two-year period, with no cost-sharing requirement, and applications are due by December 20, 2024. For further inquiries, applicants can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-012.html.
    NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the NHLBI Early Phase Clinical Trials (R33), aimed at supporting investigator-initiated Phase I clinical trials for therapeutic and diagnostic interventions targeting heart, lung, blood, and sleep (HLBS) disorders. Applicants are required to be prepared to initiate their clinical trials within the first quarter of the project period and must demonstrate readiness in obtaining necessary regulatory approvals, including FDA and IRB, prior to the award. This funding is crucial for addressing unmet medical needs through innovative research, with a maximum budget of $1.515 million per year and a project duration of up to three years, contingent upon achieving specific milestones. Interested applicants should note the application deadline of June 4, 2024, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov for further details.
    NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Heart, Lung, and Blood Institute (NHLBI), has announced a funding opportunity (FON: PAR-24-173) aimed at supporting Phase I clinical trials for therapeutics and diagnostics related to heart, lung, blood, and sleep (HLBS) disorders in both adults and children. This initiative utilizes a bi-phasic R61/R33 award mechanism, where the R61 phase focuses on preparatory activities such as finalizing trial protocols and gathering preclinical data, while the R33 phase is dedicated to executing the clinical trial. The funding limits include up to $250,000 annually for the R61 phase and $1,515,000 for the R33 phase, with total support available for a maximum of five years. Interested applicants must adhere to NIH guidelines and submit their proposals by January 7, 2027, to be considered for this opportunity. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Blueprint Medtech: Small Business Translator (U44 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Blueprint Medtech: Small Business Translator (U44 - Clinical Trial Optional)" aimed at encouraging Small Business Concerns (SBCs) to develop therapeutic and diagnostic devices for disorders affecting the nervous and neuromuscular systems. This cooperative agreement program supports activities such as clinical prototype development, non-clinical safety testing, and preparation for regulatory submissions, facilitating the translation of innovative medical device technologies into clinical applications. The program emphasizes collaboration with NIH staff and aims to include diverse and underrepresented teams while adhering to rigorous compliance standards. Interested applicants must submit their proposals by September 28, 2024, and can find additional information at the NIH grants website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for inquiries.
    Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment" funding opportunity (FOA PAR-21-166). This initiative aims to foster collaborations between academic institutions and industry to translate scientific discoveries into practical diagnostic and therapeutic solutions, specifically targeting the development of methods or tools for disease prevention, diagnosis, and treatment. The program is particularly significant as it seeks to bridge gaps in healthcare technology and enhance the effectiveness of disease management across various settings, while explicitly excluding clinical trials. Eligible applicants can receive funding up to $499,000 per year for a maximum of five years, with applications due by January 8, 2025. For further details, interested parties can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV or visit the funding announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-21-166.html.
    Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)" aimed at advancing the development of therapeutic and diagnostic devices for neurological and neuromuscular disorders. This cooperative agreement program encourages investigators to conduct translational activities and clinical feasibility studies, including the implementation of clinical prototype devices, non-clinical safety testing, and obtaining necessary regulatory approvals. The program is structured in two phases: the UG3 phase focuses on non-clinical testing to secure regulatory approvals, while the UH3 phase supports clinical studies for market application. Eligible applicants include a diverse range of institutions, such as higher education, nonprofits, and small businesses, with a particular emphasis on underrepresented groups in science. Interested parties should note that the application deadline is September 27, 2024, and can find more information at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment" (R01 - Clinical Trial Optional), aimed at fostering collaborations between academic and industrial organizations to develop innovative healthcare solutions. This initiative seeks to stimulate the translation of scientific discoveries into practical tools and methods for diagnosing and treating diseases, with a focus on interdisciplinary teamwork and addressing significant health challenges, particularly in low-resource settings. Eligible applicants can request funding up to $499,000 annually for a maximum project duration of five years, with the application deadline set for January 8, 2025. For further details, interested parties can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-21-206.html.